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Ethnopharmacological relevance: Plant-based preparations are extensively used in Surinamese folk
medicine for treating leishmaniasis, but often without a scientiﬁc rationale.
Aim of the study: To evaluate 25 Surinamese medicinal plants for their potential efﬁcacy against leish-
maniasis.
Materials and methods: Concentrated plant extracts were evaluated for their effect on the viability of L.
(V.) guyanensis AMC, L. (L.) major NADIM5, and L. (L.) donovani GEDII promastigotes, as well as in-
tracellular amastigotes of L. (L.) donovani BHU814 in infected THP-1 cells. Selectivity was assessed by
cytotoxicity against THP-1 cells.
Results: The only plant extract that showed potentially meaningful anti-leishmanial activity was that
from Solanum lycocarpum that displayed mean IC50 values of about 51, 61, and o16 mg/mL against L.
(V) guyanensis, L. (L) major, and L. (L) donovani promastigotes, respectively; about 374 mg/mL against L.
(L) donovani amastigotes; and 4500 mg/mL against THP-1 cells. The Bryophyllum pinnatum, Inga alba, and
Quassia amara extracts displayed moderate to high IC50 values against promastigotes (about 51 to
4500 mg/mL) and/or amastigotes (about 224 to 4500 mg/mL) but were relatively toxic to THP-1 cells
(IC50 values o16 to about 42 mg/mL). The remaining plant extracts exhibited in many cases IC50 values
close to, around, or above 500 mg/mL against promastigotes, amastigotes, and THP-1 cells.
Conclusions: The S. lycocarpum preparation may be useful against leishmaniasis and may have a good
safety index, warranting further investigations into its active constituents and mechanism(s) of action.
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Leishmaniasis is a parasitic disease caused by approximately
twenty different protozoan species of the genus Leishmania which
is transmitted by female sand ﬂies from at least thirty species of
Phlebotomus in the Old World and Lutzomyia in the New World to
a number of mammalian reservoirs including man (Desjeux, 2004;
Reithinger et al., 2007; World Health Organization, 2014). All
Leishmania species develop as promastigotes and amastigotes. The
promastigotes are the infectious, motile ﬂagellated forms inside
the sand ﬂy that are expelled into the host when the ﬂy draws a
blood meal (Dostálová and Volf, 2012). The amastigotes do not
have a ﬂagellum, reside and multiply inside mammalian hostr Ireland Ltd. This is an open acces
, Faculty of Medical Sciences,
bo, Suriname.macrophages, and eventually spread throughout the host’s re-
ticulo-endothelial system (Vannier-Santos et al., 2002). Clinical
disease becomes apparent within weeks to months after infection,
depending on the (sub-)species of Leishmania and the host’s im-
mune status (Vannier-Santos et al., 2002).
The clinical manifestations following Leishmania infection may
range from localized, single lesions to multiple cutaneous ulcers,
satellite lesions, or nodular lymphangitis, to disease forms with
mucosal and even potentially fatal systemic visceral involvement
(Desjeux, 2004; Reithinger et al., 2007). Currently, an estimated 12
million individuals in 98 countries throughout the world suffer
from one of these forms of leishmaniasis, approximately 350 mil-
lion people are at risk of contracting the infection, and more than
2 million disability-adjusted life years are lost annually due to this
disease (World Health Organization, 2014). These considerations
have led to the characterization of leishmaniasis as a WHO cate-
gory-1 disease, i.e., an uncontrolled and severely neglected disease
requiring increased efforts to improve vector control, diagnostics,s article under the CC BY-NC-ND license
Table 1
Relevant information about the plants evaluated in the current study. All reference vouchers are stored at the National Herbarium of Suriname (BBS) at the Anton de Kom University of Suriname, Paramaribo, Suriname (UvS:
Universiteit van Suriname; LBB: ‘s Lands Bosbeheer; TvA: Tinde van Andel; MJJ: Marjon Jansen–Jacobs).
Plant species (vernacular name in English; Surinamese) Plant family Herbarium voucher Plant part used and traditional method of usea Plant part used in current
study
Preparation of extract for current study
Allium sativum L. (Garlic; knoﬂook) Amaryllidaceae Noneb Crushed cloves are applied to sore Cloves Crushed cloves soaked for 2 h at 45 °C in
water
Aloe vera (L.) Burm.f. (Aloe; aloe) Xanthorrhoeaceae UVS-17469 Crushed leaves are smeared on sore Leaves Juice collected from crushed leaves
Anacardium occidentale L. (Cashew; kasyu) Anacardiaceae UVS-17493 Bark boiled with water and decoction applied to
sore
Bark Boiled for 1 h in water
Azadirachta indica A. Juss. (Nimtree; neem) Meliaceae UVS-17486 Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 1 h in water
Bryophyllum pinnatum (Lam.) Oken (Mother of thou-
sands; wonderblad)
Crassulaceae UVS-17498 Leaves heated above ﬁre and sore covered with
them when still hot
Leaves Boiled for 40 min in water
Cecropia peltata L. (Trumpet tree; uma busipapaya) Urticaceae TvA-4868 Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 30 min in water
Citrus aurantifolia (Christm.) Swingle Key lime; limoen) Rutaceae UVS-17472 Juice dripped on sore Fruits Juice collected at room temperature
Colocasia esculenta (L.) Schott (Taro; tayerblad) Araceae UVS-17502 Leaves heated above ﬁre and sore covered with
them when still hot
Leaves Crushed leaves soaked for 2 h at 45 °C in
water
Crescentia cujete L. (Calabash; kalebas) Bignoniaceae UVS-17436 Crushed leaves applied to sore Fruits Collect juice at room temperature (25–
26 °C)
Dieffenbachia seguine (Jacq.) Schott (Dumbcane; donke) Araceae UVS-17430 Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 1 h in water
Eclipta prostrata (L.) L. (False daisy; lowisawiwiri) Asteraceae UVS-17464 Crushed leaves applied to sore Leaves Crushed leaves soaked for 2 h at 45 °C in
water
Gossypium barbadense L. (Sea island cotton; redi katun) Malvaceae UVS-17433 Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 1 h in water
Abelmoschus esculentus (L.) Moench (Okra; oker) Malvaceae UVS-17504 Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 30 min in water
Hymenaea courbaril L. (Jatobá; loksi) Fabaceae LBB-5821 Macerated bark boiled with water and decoction
applied to sore
Bark Boiled for 2 h in water
Inga alba (Sw.) Willd. (Guavo; rode prokini) Fabaceae BBS-1075 Bark Boiled for 2 h in water
Ipomoea batatas (L.) Lam. (Sweet potato; switi patata) Convolvulaceae LBBG-16823 Mashed tubers applied to sore (for 24 h) Tubers Crushed tubers soaked for 40 min in water
at 45 °C
Mikania micrantha Kunth (Bitter vine; brokobaka) Asteraceae LBB-12491 Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 30 min in water
Morinda citrifolia L. (Cheese fruit; noni) Rubiaceae LBB-12811 Leaves heated above ﬁre and sore covered with
them when still hot
Leaves Crushed leaves soaked for 2 h at 45 °C in
water
Musa sp. (Banana; banana) Musaceae Nonec Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 20 min in water
Quassia amara L. (Amargo; kwasibita) Simaroubaceae UVS-17475 Bark boiled with water and decoction applied to
sore
Bark Boiled for 3 h in water, then left for 1 day
Senna alata (L.) Roxb. (Candle bush; slabrikiwiri) Fabaceae TvA-5088 Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 1 h in water
Solanum lycocarpum A.St.-Hil. (Wolf apple; uma parabita) Solanaceae UVS-17489 Juice from leaves applied to sore Leaves Leave juice collected at room temperature
Spondias mombin L. (yellow mombin; mope) Anacardiaceae LBB-12479 Bark boiled with water and decoction applied to
sore
Bark Boiled for 1 h in water
Uncaria guianensis (Aubl.) J.F.Gmel. (Cat’s claw; popokay
nangra)
Rubiaceae UVS-16826 Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 2 h in water
Vismia guianensis (Aubl.) Pers. (Bloodwood; pinya wiwiri) Hypericaceae 6308-MJJ Leaves boiled with water and decoction applied to
sore
Leaves Boiled for 1 h in water
a According to Ramdas (2015).
b The current study used commercially available garlic cloves.
c No voucher number available as the exact species could not be determined.
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Cutaneous leishmaniasis (CL) is endemic and the principal form
of leishmaniasis in the Republic of Suriname (South-America),
where it is locally known as bosyaws or busiyasi (Flu, 1911; Van der
Meide et al., 2008c). This condition is mainly caused by Leishmania
(Viannia) guyanensis (Lai et al., 2002; Van der Meide et al., 2008c),
but other Leishmania species such as L. (V) naifﬁ and Leishmania
(Leishmania) amazonensis, have also been identiﬁed in the country
(Van der Meide et al., 2008a, 2008b; Van Thiel et al., 2010; Hu
et al., 2012). CL is particularly prevalent in Suriname’s rural-in-
terior hinterland. Its victims are in general individuals who intrude
into the parasites’ habitat such as residing Indigenous and Maroon
people as well as eco-tourists, recreational hunters and ﬁshers,
and personnel of gold mining, bauxite mining, and logging com-
panies (Van der Meide et al., 2008c). This has led in the year 2008
to 5.32–6.13 infections per 1000 inhabitants for Suriname’s hin-
terland, and 0.64–0.74 per 1000 for the entire country (Van der
Meide et al., 2008c).
The current ﬁrst-line drug and the only treatment option for CL
caused by L. (V.) guyanensis in Suriname is pentamidine isethionate
administered with three intramuscular injections of 300 mg each
during a seven-day period (Lai et al., 2002). Unfortunately, this
drug - developed more than ﬁfty years ago - is rather toxic and
prone to cause resistance (Croft et al., 2006). Furthermore, poor
compliance - probably attributable to the lack of adequate health
education - may lead to incomplete therapy and sub-therapeutic
drug levels in the plasma, another reason for the development of
drug-tolerant parasites (Croft et al., 2006). Notably, the substantial
expenses for treatment and transportation to health centers in
Paramaribo together with loss of income due to the inability to
work, often represent considerable obstacles for affected in-
dividuals to seek medical treatment.
These considerations may lead patients to attempt self-treat-
ment, using, among others, traditional plant-based remedies
(Ramdas, 2015). Contributing to this inclination is Suriname’s
comprehensive ethnobotanical knowledge (Van Andel and Ruys-
schaert, 2011) and unique plant biodiversity that provides ample
raw material to be processed into ethnopharmacological pre-
parations for treating CL (DeFilipps et al., 2004). So far, however,
the scientiﬁc evidence to support the therapeutic usefulness of
these substances is scant. If efﬁcacious, some of them may re-
present lead compounds for the development of novel drugs for
treating CL. For this reason, a number of plants that are used in
Suriname against this disease were evaluated for their activity
against cultured promastigotes and amastigotes from various
Leishmania species including L. (V.) guyanensis. To obtain an in-
dication about the selectivity of the plant preparations, their po-
tential anti-leishmanial effect was compared with their cytotoxi-
city against cultured human THP-1 monocytic cells. In all cases, the
well-established anti-leishmanial drug amphotericin B served as a
reference compound.2. Materials and methods
2.1. Plant collection and preparation of plant extracts
The plants investigated in the current study were selected on
the basis of a previous comprehensive survey on ethnopharma-
cological remedies for treating CL (Ramdas, 2015). The survey in-
volved a series of open non-structured interviews with members,
key informants, and traditional practitioners of Indigenous and
Maroon communities as well as gold mining workers in the in-
terior of Suriname who are knowledgeable about traditional forms
of treatment of CL (Ramdas, 2015). The interviews were conducted
in the period 2010–2011, and provided information 25 plants thatare ethnopharmacologically used for treating CL, the plant parts
used, their use as dried or fresh preparations, and the methods of
extraction (Table 1). This information was cross-checked with
previously published data on plants that are traditionally used for
treating CL compiled by De Filipps et al. (2004) and Van Andel and
Ruysschaert (2011).
On the basis of this information, the indicated plant parts were
collected in Suriname’s hinterland in areas that had been free of
herbicidal or pesticidal use for at least the preceding six months.
The collections were done in close collaboration with the National
Herbarium of Suriname that is in the possession of a collection
permit from the Surinamese Ministry of Physical Planning, Land-
and Forestry Management. Notably, none of the collected plants
are on the International Union for Conservation of Nature’s Red
List of endangered or threatened species (IUCN, 2015).
The collected samples were thoroughly washed with distilled
water, dried in open air, washed again, processed as indicated in
Table 1, ﬁltered, freeze-dried so as to obtain a stable powder, and
divided in aliquots of 2 g which were stored at 20 °C before
being shipped on dry ice to The Netherlands. The plant extracts
were subsequently liqueﬁed in ultra-pure water to a concentration
of 10 mg/mL and further dissolved by shaking for 1 h at 50 °C. The
suspensions were then centrifuged for 5 min at 3000 rpm after
which the supernatants were collected, sterilized through 0.22 mM
ﬁlters (Millipore), and stored at 20 °C until tested.
2.2. Drugs and chemicals
Fetal bovine serum (FBS), phorbol 12-myristate 13-acetate
(PMA), tris(hydroxymethyl)-aminomethane) (Tris), ethylene-
diamminetetraacetic acid (EDTA), phenylmethanesulfonyl ﬂuoride
(PMFS), nicotinamide adenine dinucleotide phosphate (NADPH),
and 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) were from Sigma-
Aldrich Co (St. Louis, MO, USA). Alamar Blue dye was from AbD
Serotec (Düsseldorf, Germany), RPMI 1640 medium from Life
Technologies (Bleiswijk, The Netherlands), Triton X-100 from BDH
Laboratory Supplies (Poole, UK), and trypanothione disulﬁde
(T[S]2) from Bachem AG (Budendorf, Switzerland). All other che-
micals used were from the laboratory stock of the Parasito
logy Unit, KIT Biomedical Research, Royal Tropical Institute
(Amsterdam, The Netherlands), and were of the highest grade
available.
2.3. Maintenance and culture of leishmania parasite isolates and
THP-1 cells
The promastigote forms of L. (V.) guyanensis (strain AMC 2014),
L. (L.) major (strain MHOM/IR/1972/NADIM5), and L. (L.) donovani
(strain GEDII, a fresh isolate from Gaderif State, Sudan maintained
in the KIT Biomedical Research laboratory since 2013, or strain
BHU-814, a recent isolate from Bihar State, India, which is only
used for the amastigote drug susceptibility assay) were cultured
axenically in RPMI 1640 medium containing 25 mM HEPES and
2 mM L-glutamine and supplemented with 15% (v/v) heat-in-
activated FBS, 100 IU/mL penicillin, and 100 mg/mL streptomycin.
The promastigotes were maintained at 27 °C by weekly sub-cul-
turing. The L. guyanensis AMC 2014 strain (donated by the Aca-
demic Medical Centre, Amsterdam, The Netherlands) which was
recently isolated from a patient in Suriname, was originally
maintained in NNN medium but adapted to the supplemented
RPMI 1640 medium for the current study.
THP-1 human acute monocytic leukemia cells (Tsuchiya et al.,
1980) were from ATCC (no. TIB 202) and maintained in RPMI 1640
medium containing 25 mM HEPES and 2 mM L-glutamine and
supplemented with 10% (v/v) heat-inactivated FBS, 100 IU/mL pe-
nicillin, and 100 mg/mL streptomycin at 37 °C at a minimum
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2.4. Promastigote and THP-1 cell drug susceptibility assay
Susceptibility of Leishmania promastigotes and THP-1 monocytic
cells to the plant extracts was assessed as previously described by
van den Bogaart et al. (2014). In brief, triplicate cultures of pro-
matigotes of L. guyanensis AMC, L. major NADIM5, and L. donovani
GEDII, at densities of 2  105 parasites/100 μL, or 2  104 THP-1
monocytic cells/100 μL medium per well in 96-well ﬂat-bottomed
microplates, were exposed to the plant extracts at serial dilutions of
500–15,625 mg/mL. L. (L.) major also causes CL but is not present in
Suriname, while L. (L.) donovani causes visceral leishmaniasis and is
also not present in Suriname. However, the promastigotes from L.
major NADIM5 and L. donovani GEDII have been incorporated in the
study besides those from L. guyanensis AMC, in order to determine
whether or not the test compounds exhibited speciﬁcity for
(a) particular Leishmania species. Incubations were for 72 h in ﬁnal
volumes of 200 μL per well. Amphotericin B at serial dilutions
ranging from 0.0007 to 0.231 mg/mL served as a reference com-
pound, and untreated parasites or THP-1 cells incubated with
medium only were used as controls. The use of amphotericin B as a
reference compound rather than pentamidine isethionate was
based on the previous assessment of the efﬁcacies of miltefosine,
pentamidine, amphotericin B, and paromomycin as standard drugs
against L. donovani and L. major promastigotes and intracellular
amastigotes that showed that the two former compounds - unlike
the two latter - exhibited differential effects toward the different
parasite species and developmental stages (van den Bogaart et al.,
2014).
At the end of the incubations, responses of the parasite and
monocyte cultures were assessed using a method based on
staining with Alamar Blue dye (Mikus and Steverding, 2000). A
number of pilot experiments performed in our laboratory in-
dicated that the plant extracts (alone) interfered with the Alamar
Blue reduction. For this reason, the method was slightly modiﬁed
in order to enhance its performance. Thus, the contents of the ﬂat-
bottomed plates was transferred to V-bottomed plates which were
centrifuged for 10 min at 3000g, the supernatants were discarded,
and the pelleted parasites or THP-1 cells were re-suspended in
100 mL complete RPMI medium containing 10% (w/v) Alamar Blue
dye. After thorough mixing, the contents of the V-bottomed plates
was transferred back to new ﬂat-bottomed plates which were
incubated for 4.5 h at 27 °C in the case of the promastigotes and
for 2 h at 37 °C and 5% CO2 in the case of the THP-1 cells.
After incubation, ﬂuorescence was measured with an Inﬁnite
M200Pro multimode plate reader (Tecan, Männedorf, Switzerland)
using excitation and emission wavelengths of 560 and 590 nm, re-
spectively, and the values obtained were plotted against plant ex-
tract concentrations after correction for background ﬂuorescence.
The latter was determined from blank wells which had received
medium only. Dose–response proﬁles were constructed and a non-
linear regression analysis (GraphPad Prism 5.03, San Diego, CA) was
performed to obtain the IC50 values i.e., plant extract concentrations
resulting in 50% inhibition of the growth of the parasites or the
monocytes when compared to untreated controls.
2.5. Amastigote drug susceptibility assay
This procedure has been described in detail by van den Bogaart
et al. (2014). It should be noted that this assay has been set-up for
L. donovani BHU-814 strain only as it was previously shown that L.
major, L. guyanensis and L donovani GEDII failed to efﬁciently infect
the THP-1 cells (infection grade less than 30%). Therefore, theamastigote-phagocyte assay could not be validated with these
strains, and the L. donovani BHU814 was used instead.
In brief, triplicate cultures of THP-1 monocytic cells were in-
oculated at densities of 1  105/200 mL per well in 96-well ﬂat-
bottomed microplates and stimulated for 48 h with 10 ng/mL PMA
to obtain differentiated, non-dividing macrophage-like cells. After
removing the PMA by three times washing with medium, the THP-
1 cells were subjected to infection by stationary-growth phase
promastigotes of L. donovani BHU-814 (5-day old cultures) at a
ratio of 10 parasite per THP-1 cell. The use of stationary growth
phase promastigotes was based on the fact that there are more
metacyclic promastigotes in this growth phase which can infect
the macrophages more efﬁciently (Inocêncio da Luz et al., 2009).
Sixteen hours later, promastigotes that had failed to infect the
macrophages were removed by washing three times with RPMI
1640 medium. Next, infected cells were exposed to the plant ex-
tracts at serial dilutions (range 500–15,625 mg/mL) or to medium
only (untreated control). A blank comprising uninfected THP-1
cells with no exposure to plant extracts was also included. Am-
photericin B was used as a reference compound (positive control
for drug action) at serial dilutions ranging from 0.007 to
0.231 mg/mL. All incubations were for 96 h at 37 °C and at 5% CO2.
At the end of the incubations, the number of infected monocytes
was assessed using the Leishmania-speciﬁc trypanothione reductase
(TryR)-based assay (van den Bogaart et al., 2014). To this end, cells were
ﬁrst washed and then incubated for 15min with a lysing buffer con-
sisting of 2% (w/v) Triton X-100 in PBS supplementedwith 1mMEDTA,
40 mM HEPES, and 1mM PMFS and buffered with 50mM Tris pH 7.5.
Of each lysate, 75 mL was transferred to the wells of 96-well micro-
plates and incubated for 3 h at 27 °C with 200 mMNADPH (25 mL), 75 m
MT[S]2 (75 mL), and 100 mM DTNB (25 mL). Absorbances were mea-
sured with an Inﬁnite M200Pro multimode plate reader (Tecan, Män-
nedorf, Switzerland) at a wavelength of 412 nm, and corrected for the
corresponding blanks where T[S]2 was replaced by Tris 0.05 M buffer
pH 7.5. The inhibition of parasite growth was determined by compar-
ison of the signal produced by drug-treated parasites with that of
untreated control parasites. Non-linear regression was used for curve
ﬁtting and calculation of 50% inhibitory concentrations (IC50 values).
2.6. Data processing
All experiments have been carried out at least three times, and
the data obtained have been expressed as means with 95% con-
ﬁdence intervals (CIs) and are given in Table 2. Comparisons for
statistically signiﬁcant differences have been done with Student’s t
test, and p valueso0.05 have been taken to indicate statistically
signiﬁcant differences.
2.7. Ethical considerations
The studies described by Ramdas (2015) including the inquiries
about the plants traditionally used for treating CL, have been ap-
proved by the Surinamese national health and village authorities.
This included approval from the Committee for Research Involving
Human Subjects from the Surinamese Ministry of Health (ﬁle
number VG 006–2009), as well as from the captains and tradi-
tional chiefs of the villages where the interviews with individuals
holding information about traditional forms of treatment of CL
took place. Prior to each interview, an explanatory text was read to
each village head and each informant in his/her native language,
and an informed consent form was signed to conﬁrm that the
person’s participation was voluntary.
Table 2
IC50 values (95% CI) of L. guyanensis AMC, L. major NADIM5, and L. donovani GEDII promastigotes, L. donovani BHU814 amastigotes, and THP-1 cells in response to exposure to
amphotericin B or plant extracts.
IC50 (mg/mL)
L. guyanensis AMC promastigotes L. major NADIM5 promastigotes L. donovani GEDII promastigotes L. donovani BHU814
amastigotes
THP-1 cells
Amphotericin B 0.012 (0.011–0.013) 0.032 (0.028–0.034) 0.035 (0.024–0.052) 0.012 (0.011–0.046) 4 0.231
A. esculentus 4 500 4 500 4 500 4 500 4 500
A. sativum 340 (208–555) 4 500 4 500 396 (7–20,863) 364 (155–856)
A. vera 4 500 4 500 4 500 4 500 4 500
A. occidentale 4 500 230 (133–396) 395 (277–562) 4 500 169 (113–252)
A. indica 4 500 187 (152–231) 247 (170–358) 451 (112–1,821) 352 (299-85)
B. pinnatum 4 500 4 500 4 500 4 500 42 (21–85)
C. peltata 354 (299–419) 424 (344–524) 321 (278–370) 4 500 312 (115–415)
C. aurantifolia 4 500 4 500 4 500 4 500 4 500
C. esculenta 4 500 4 500 4 500 4 500 4 500
C. cujete 4 500 4 500 4 500 4 500 4 500
D. seguine 4 500 4 500 4 500 4 500 4 500
E. prostrata 4 500 4 500 4 500 4 500 4 500
G. barbadense 4 500 4 500 4 500 4 500 156 (116–211)
H. courbaril 306 (211–443) 341 (287–405) 297 (203–435) 4 500 130 (95–177)
I. alba 435 (312-606) 298 (230–385) 205 (49–2339) 224 (96–524) o 16
I. batatas 4 500 427 (347–526) 4 500 4 500 4 500
M. micrantha 4 500 4 500 402 (351–460) 403 (283–825) 128 (43–378)
M. citrifolia 4 500 4 500 4 500 4 500 4 500
Musa sp. 4 500 4 500 4 500 4 500 4 500
Q. amara 4 500 51 (44–60) 68 (60–77) 288 (10–8477) o 16
S. alata 4 500 4 500 4 500 4 500 4 500
S. lycocarpum 51 (36-73) 61 (45–178) o 16 374 (289–405) 4 500
S. mombin 4 500 4 500 4 500 4 500 209 (169–260)
U. guianensis 4 500 4 500 4 500 4 500 337 (251–452)
V. guianensis 4 500 426 (329–554) 401 (359–449) 4 500 153 (67–352)
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3.1. Growth responses of promastigotes, amastigotes, and THP-1 cells
to amphotericin B
As shown in Table 2, amphotericin B was active against L. guya-
nensis AMC, L. major NADIM5, and L. donovani GEDII promastigotes,
as well as against L. donovani BHU814 amastigotes, displaying IC50
values that ranged from about 0.012 to about 0.035 mg/mL, but in-
hibited the growth of THP-1 cells at 12- to 72-fold higher con-
centrations. This observation is in agreement with previous ob-
servations (van den Bogaart et al., 2014) and validates the use of the
promastigote and amastigote-phagocyte assay for evaluating the
potential anti-leishmanial efﬁcacy of the plant extracts.
3.2. Growth responses of promastigotes, amastigotes, and THP-1
cells to the extract from Solanum lycocarpum A.St.-Hil.
Table 2 summarizes the growth responses of L. guyanensis AMC,
L. major NADIM5, and L. donovani GEDII promastigotes, L. donovani
BHU814 amastigotes, and THP-1 cells to the 25 plant extracts
evaluated in the current study.
The preparation from Solanum lycocarpum A.St.-Hil. elicited the
greatest anti-leishmanial activity, displaying cytotoxic effects
against L. guyanensis AMC, L. major NADIM5, and L. donovani GEDII
promastigotes at IC50 values of 51 (36–73), 61 (45–178), and
o16 mg/mL, respectively. This preparation produced a much
higher IC50 value in L. donovani BHU814 amastigotes-374 (289–
405) mg/mL-but had hardly any effect on the growth of THP-1 cells
at the concentration tested (IC50 value 4500 mg/mL). These ob-
servations suggest that the S. lycocarpum extract was relatively
toxic to the Leishmania promastigotes and did not affect normal
human cells, but was only moderately active against Leishminia
amastigotes.3.3. Growth responses of promastigotes, amastigotes, and THP-1
cells to the extracts from Bryophyllum pinnatum (Lam.) Oken, Inga
alba (Sw.) Willd., and Quassia amara L.
The extract from Bryophyllum pinnatum (Lam.) Oken had al-
most no effect on the growth of L. guyanensis AMC, L. major NA-
DIM5, and L. donovani GEDII promastigotes as well as that of L.
donovani BHU814 amastigotes (IC50 values 4500 mg/mL; Table 2)
but was relatively toxic towards the THP-1 cells (IC50 value of 42
(21–85) mg/mL; Table 2).
The extra ct from Inga alba (Sw.) Willd. also inhibited the
growth of the promastigotes and amastigotes at relatively high
IC50 values (205–435, and 224 mg/mL, Table 2), but was highly
toxic towards the THP-1 cells (IC50 value of o16 mg/mL).
And the Quassia amara L. sample had almost no effect on the
growth of L. guyanensis AMC promastigotes (IC50 value
4500 mg/mL), but inhibited that of L. major NADIM5 and L. do-
novani GEDII promastigotes at IC50 values of 51 and 68 mg/mL,
respectively (Table 2), and that of L. donovani BHU814 amastigotes
at the relatively high IC50 value of 288 mg/mL (Table 2). However,
this preparation was, similarly to the I. alba extract, highly cyto-
toxic against THP-1 cells (IC50 value o16 mg/mL.
Together, these observations suggest that the B. pinnatum, I.
alba, and Q. amara extracts were (much) more toxic to normal cells
than to Leishmania promastigotes or amatigotes, and/or that their
toxicity to normal human cells surpassed their potential anti-
leishmanial activity.
3.4. Growth responses of promastigotes, amastigotes, and THP-1
cells to the remaining plant extracts
The remaining plant extracts were hardly cytotoxic to promas-
tigotes, amastigotes, and THP-1 cells, displaying IC50 values that
ranged from 100 mg/mL to (far) in excess of 500 mg/mL (Table 2).
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In this study, 25 plant extracts from Suriname have been
evaluated for their potential efﬁcacy against Leishmania parasites
using a promastigote and an amastigote–macrophage assay, as
well as against cultured human THP-1 monocytic cells to assess
their selectivity. Unfortunately, the Leishmania species most im-
portant for Suriname - L. (V.) guyanensis - showed a very low
THP1-infecting grade and could therefore not be incorporated in
the amastigote–macrophage assay. L. (V.) guyanensis was earlier
reported as notoriously inefﬁcient to infect macrophages (In-
ocêncio da Luz et al., 2009), and therefore we had to use the L.
donovani-based amastigote assay in this case. Nevertheless, the
most promising outcome of the present study was that the extract
from S. lycocarpum leaves was relatively toxic towards the pro-
matigotes while hardly affecting the viability of the THP1 cells.
This suggests that this phytocomplex may possess useful anti-
leishmanial properties while exhibiting low cytotoxicity against
human cells.
Partial support for the apparent anti-leishmanial activity of the
S. lycocarpum preparation highlighted by the current study is
provided by the signiﬁcant anti-leishmanial effect of solamargine
and solasonine - the principal glycoalcaloids in the fruits of
S. lycocarpum - displayed in vitro activity towards promastigotes of
L. (L.) amazonensis (Miranda et al., 2013). These compounds ex-
hibited IC50 values that were lower than those found in parallel
experiments against cultured LLC-MK2 rhesus monkey kidney
cells (Miranda et al., 2013), indicating that the cytotoxic effects of
the glycoalkaloids were fairly Leishmania-speciﬁc. Notably, sola-
margine and solasonine are also present in the leaves of S. lyco-
carpum (Tiossi et al., 2012) as well as in various parts of many
other members of the plant family Solanaceae (Bajak et al., 1979;
Jaggi and Kapoor, 1994).
However, it should not be overlooked that the S. lycocarpum
extract was only modestly cytotoxic against L. donovani amasti-
gotes in the current study. Indeed, in vitro activity against this
mammal-infective stage of Leishmania is clinically much more
more relevant than activity against the insect-infective stage of the
parasite (De Muylder et al., 2011). Furthermore, screening of can-
didate compounds against the promastigote assay reportedly leads
to the identiﬁcation of 50% false positives, necessitating re-eva-
luation of the test compounds with the more appropriate amas-
tigote assay (De Muylder et al., 2011). For these reasons, the cur-
rent results with the S. lycocarpum preparation, even though en-
couraging, should be regarded with caution.
Still, it is important to note that preparations from Solanum
species are extensively used in various parts of the world for
treating CL. Examples are the leaves of S. americanum (Mill.) in an
endemic area in Bahia, Brazil (França et al., 1996); the leaves and
fruits of S. nigrum L, Nicotiana tabacum L., and/or Capsicum annuum
L. in rural Ecuador (Weigel and Armijos, 2001); the fruits of S
straminifolium var. straminifolium Jacq. and the aerial part of S.
peruvianum L. by the Chayahuita and the Yanesha ethnic groups,
respectively, in Peru (Estevez et al., 2007; Valadeau et al., 2009);
and the bark of S. crinitum Lam. and S. subinerme Jacq. by the
Wayãpi Amerindian of the Oyapock basin in French Guiana and
other parts of the Guiana Shield (Odonne et al., 2011). Testing of
ethanol extracts of the two latter samples along with chloroform
extracts of the aerial parts of S. sisymbriifolium Lam. revealed
moderate to high activity against amastigotes and/or promasti-
gotes of L. (L.) amazonensis and/or L. (V.) braziliensis (Estevez et al.,
2007; Valadeau et al., 2009; Cechinel Filho et al., 2013). These
ﬁndings further support the potential anti-leishmanial activity of
the S. lycocarpum leaf extract observed in the current study. More
comprehensive in vitro, in vivo, and clinical studies should more
deﬁnitely establish the value of such a preparation in thetreatment of CL.
Preparations from B. pinnatum, I. alba, and Q. amara are used
against CL by, among others, certain rural communities in Ecuador
(Gachet et al., 2010), an Indigenous community in Junín, Peru
(Luziatelli et al., 2010), the above-mentioned Wayãpi Amerindians
from the Guiana Shield (Odonne et al., 2011), and the inhabitants
of the Bandundu province in DR Congo (Musuyu Muganza et al.,
2012). Furthermore, there is some preclinical and clinical evidence
for anti-leishmanial activity of the two former preparations (Rossi-
Bergmann, 2000; Torres-Santos et al., 2003; Bhattacharjee et al.,
2009).
However, the results from the current study showed that these
plant extracts affected the viability of the THP-1 cells at relatively
low concentrations while displaying only modest or hardly any
activity against Leishmania promastigotes or amatigotes. This
suggests that these samples contain substances that are highly
cytotoxic but lack meaningful leishmanicidal activity. The former
supposition is supported by the presence - at least in Q. amara
preparations - of highly cytotoxic quassinoids that often exert in
vitro cytotoxic effects against cancer cells at (much) lower con-
centrations when compared to, for instance, their antimalarial and
antileishmanial effects (Xu et al., 2000; Guo et al., 2005; Mu-
hammad and Samoylenko, 2007; Houël et al., 2009). Support for
the latter suggstion comes from reports mentioning that the active
constituents of B. pinnatum and Q. amara extracts - ﬂavonoids
(Muzitano et al., 2006, 2009) and quassinoids (Bhattacharjee et al.,
2009), respectively - do not exert direct cytotoxicity against the
parasites, but improve the host’s immune response to Leishmania
infection (Bhattacharjee et al., 2009) and activate the reactive ni-
trogen intermediates pathway of macrophages (Da Silva et al.,
1995, 1999; Kolodziej et al., 2001), respectively. Future studies
should verify these suppositions and account for the apparently
high cytotoxicity of the I. alba preparation.
The remaining plant extracts were virtually ineffective towards
Leishmania promastigotes and amastigotes as well as THP-1 cells.
Thus far, there are no experimental data available about a possible
anti-leishmanial activity of preparations from C. esculenta, C. cu-
jete, G. barbadense, A. esculentus, I. batatas, and U. guianensis.
However, the negative results with preparations from A. occi-
dentale, C. peltata, D. seguine, E. prostrata, M. paradisiaca, S. alata,
and V. guianensis are in accordance with the nonexistent or rela-
tively modest anti-leishmanial effects in cultured promastigotes
and/or amastigotes from various Leishmania species exposed to an
ethanolic extract from the stem bark of A. occidentale (Braga et al.,
2007); alcoholic extracts of C. peltata (García et al., 2012); pre-
parations from D. seguine and its family members D. aff. costata H.
Karst. ex Schott and D. williamsii Croat (Grenand et al., 2004; Es-
tevez et al., 2007; Valadeau et al., 2009); saponins from E. prostrata
(Khanna et al., 2014); fractions of an ethanolic extract of M.
paradisiaca (Accioly et al., 2012); ethanolic extracts from leaves
and roots of S. alata (Espinoza et al., 2009); and ethanolic extracts
from the bark of the Vismia species V. tomentosa Ruiz and Pav.
(Estevez et al., 2007) and from bark, leaves, and stem of V. baccifera
(L.) Triana and Planch, V. pozuzoensis Engl., and Vismia sp., re-
spectively (Valadeau et al., 2009).
On the other hand, the lack of anti-leishmanial effects of the A.
sativum, A. vera, A. indica, C. aurantifolia, H. courbaril, M. micrantha,
and S. mombin extracts noted in the current study is at variance
with literature data reporting the opposite (Da Silva et al., 1995;
Torres-Santos et al., 2003; Khalid et al., 2005; Arruda et al., 2009;
Accioly et al., 2012; Carneiro et al., 2012; Iqbal et al., 2012; Laurella
et al., 2012; Ribeiro et al., 2014). However, in at least some of these
cases, these apparent discrepancies might be attributed to differ-
ences in experimental conditions. For instance, rather than with
water, various of the samples mentioned in the literature had been
extracted with methanol (A. vera leaves; Iqbal et al., 2012), ethanol
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et al., 2012), or apolar solvents (A. indica fruits, Carneiro et al.,
2012; M. micrantha leaves, Laurella et al., 2012; H. courbaril leaves,
Ribeiro et al., 2014). Also, instead of a preparation from the stem
bark, the current study evaluated an extract from the leaves of M.
citrifolia, while the former rather than the latter sample was ef-
fective in patients with CL caused by L. (L.) major (Sattar et al.,
2012; Siddiqui et al., 2014).
Summarizing, the results from this study suggest that pre-
parations from S. lycocarpum could potentially be used for treating
CL while causing tolerable side-effects. In light of the lack of efﬁ-
cacious forms of CL treatment, this observation makes this plant
an interesting candidate for new drug development programs. On
the other hand, preparations from B. pinnatum, I. alba, and Q.
amara should be avoided because of apparently little therapeutic
beneﬁt but the possibility of excessive toxicity. At this moment,
preparations are being made to identify the pharmacologically
active principle(s) in the S. lycocarpum extract applying bioassay-
guided puriﬁcation. Also, the plant extracts that turned out in-
active in the current study but have been reported by others to
possess leishmanicidal properties, will be retested under more
appropriate experimental conditions.References
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